Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05069740

Endometriosis and Microvascular Dysfunction: Role of Inflammation

The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction.

Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

The Pennsylvania State University

University Park, Pennsylvania, 16801, United States

Location status: Recruiting

Location contact

Lacy M Alexander, PhD

CONTACT

[email protected]

814-867-1781

About this study

Endometriosis is an estrogen-dependent gynecological disorder associated with considerable chronic pelvic pain, pain during intercourse, and is a major cause of infertility. This disorder affects 6% - 10% of reproductive age women and can be as high as 35-50% in women experiencing pain or infertility. Endometriosis derives from the presence of endometrium-like tissue in sites outside the uterine cavity. While endometriosis is a local inflammatory syndrome, the inflammatory process is systemic.

Endometriosis is associated with higher risk of hypercholesterolemia and hypertension 8. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk.

Endometriosis a disease of inflammation and increased systemic inflammatory cytokine production, although the precise mechanisms by which localized lesion results in systemic inflammation are incompletely understood. Published data confirm an elevation of several inflammatory cytokines in the circulation of women with endometriosis. Alterations in circulating miRNAs specific to endometriosis are one mechanism causing immune dysfunction and subsequent increased cytokine expression in areas remote from the endometriotic lesions. This aberrant increase in systemic cytokine production is a highly plausible putative link to accelerated vascular dysfunction and atherosclerosis in women with endometriosis.

The circulating factors LDL and oxidized LDL are two of the many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 is a ubiquitously expressed scavenger receptor, stimulated by oxLDL, Ang II, and other inflammatory cytokines, and inhibited by estrogen. LOX-1 is the upstream signaling initiator of mechanisms including increased oxidant production, reduced nitric oxide (NO) metabolism, and impaired intracellular trafficking. Thus, LOX-1 signal transduction functionally results in pronounced endothelial dysfunction.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy women between the ages of 18 and 45 years (Controls), taking oral contraceptive or with regular menses every 26-34 days
  • Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician <5 years prior, and reported by the subject to the researchers)
  • Tylenol if the subject has acute pain is allowed
  • Contraceptive use is allowed

Exclusion criteria

  • Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)
  • Diabetes (HbA1C 6.5%)
  • BP>140/90
  • Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)
  • Pregnancy
  • Breastfeeding
  • Taking illicit and/or recreational drugs
  • Abnormal liver function
  • Rash, skin disease, disorders of pigmentation, known skin allergies
  • Diagnosed or suspected metabolic or cardiovascular disease
  • Persistent unexplained elevations of serum transaminases
  • Known allergy to latex or investigative substances (including salsalate or simvastatin)
  • History of gastrointestinal bleeding

Treatment and study plan

Salsalate Pill

Drug

Salsalate acts as an NFkB inhibitor to reduce systemic inflammation

Placebo

Drug

Placebo for the salsalate intervention

Primary outcomes

  1. cutaneous vascular conductance

    Time frame: 5 days after treatment

    doppler flowmetry used to measure cutaneous vascular conductance (cvc = red cell flux/mean arterial pressure) to assess microvascular endothelial function

  2. brachial artery diameter and blood flow velocity

    Time frame: 5 days after treatment

    continuous ultrasound imaging measurements of brachial artery diameter and blood flow velocity to assess endothelial function

  3. Sera LOX-1 protein expression

    Time frame: 5 days after treatment

    Peripheral Blood Mononuclear Cell Isolation, LOX-1 expression quantified using real time pCR

  4. Biopsy LOX-1 protein expression

    Time frame: 5 days after treatment

    Bio-Rad DC assay, western blot technique used for LOX-1 protein receptor expression

Secondary outcomes

  1. sera reproductive hormone analysis

    Time frame: 5 days after treatment

    analysis of plasma estradiol, progesterone, and sex hormone binding globulin determined through hormone assay

  2. sera cytokine expression analysis

    Time frame: 5 days after treatment

    expression of cytokines CRP, TNF-a, IL-1B, IL-6, IL-8 determined through multiplex assay

  3. skin biopsy biochemical analysis

    Time frame: 5 days after treatment

    the expression of estrogen receptor alpha and beta, the protein pVASP/VASP, and the enzyme peNOS/eNOS is determined using Bio-Rad DC assay, western blot technique

Study contacts

Contact information is provided by the study sponsor or research team.

Lacy M Alexander, Ph.D.

CONTACT

[email protected]

8148671781

Susan Slimak, RN

CONTACT

[email protected]

814-863-8554

Sponsors and collaborators

Lead sponsor

Penn State University

Other

Registry information

Official study title

Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis

Acronym: Endo3/SA2

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Oct 6, 2021
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.